Komori
Governance4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Corporate Governance Report 2026/06/29

The report includes a skills matrix showing the composition and skills of the Board of Directors. The Board operates as a company with an Audit and Supervisory Committee, and voluntary bodies including the Group Nomination Committee and Group Compensation Committee have also been established.

Worth reading
77Important
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Board of Directors13 membersof which 8 outside61.5%
Half
OutsideIn-house

社外取締役は、その会社の出身ではない取締役です。半数の線を超えると、取締役会の多数を社外の人が占めることになります。The percentage represented by the dotted line was calculated from the publicly disclosed number of people.

Committee5
Audit and Supervisory CommitteeGroup Nomination CommitteeGroup Compensation CommitteeESG CommitteeGroup Compliance Promotion Committee
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directorsTotal number 13 / Of which, outside 8 independent officers
CommitteeName Audit and Supervisory Committee, Group Nomination Committee, Group Compensation Committee, ESG Committee, Group Compliance Promotion Committee / Percentage of outside members Not disclosed
Items this document does not state (5)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To achieve the goals of the medium-term management plan, directors need knowledge, experience and a track record in corporate management, research and development and intellectual property, sales and marketing, medicine and pharmacy, global business, finance and accounting, legal affairs and risk management, and sustainability and ESG.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/06/29 | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori